Press releases – BioArctic

Invitation to presentation of BioArctic’s fourth quarter report for October – December 2022 on February 3 at 9.30 a.m. CET

January 25, 2023 - Other press release

Stockholm, Sweden, January 25, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s fourth quarter report for October – December 2022 on ...

BioArctic’s partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease

January 7, 2023 - Other press release

Stockholm, January 7, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today they have submitted a supplemental Biologics License Application (sBLA) to ...

BioArctic moves to Nasdaq Stockholm Large Cap

January 2, 2023 - Other press release

Stockholm, January 2, 2023 – As of today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will move to the Large Cap listing on the Nasdaq Stockholm ...

BioArctic’s partner Eisai publishes statement relating to article on lecanemab in Scienceinsider

December 23, 2022 - Other press release

Stockholm, December 23, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a statement regarding an article on the safety of lecanemab ...

BioArctic’s partner Eisai initiates BLA submission of data for lecanemab in China

December 23, 2022 - Other press release

Stockholm, December 23, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated submission of data for Biologics License ...

Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference

November 21, 2022 - Other press release

Stockholm, November 21, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the efficacy, safety and biomarker results from the Phase 3 ...

BioArctic expands portfolio with alpha-synuclein Brain Transporter project

November 17, 2022 - Other press release

Stockholm, November 17, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company is expanding its alpha-synuclein project portfolio. The new project, ...

BioArctic receives new patent in the US for blood-brain barrier transport technology

November 14, 2022 - Other press release

Stockholm, November 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted BioArctic a ...

BioArctic develops new treatment for Gaucher’s disease

November 8, 2022 - Other press release

Stockholm, November 8, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has initiated a new project focused on enzyme replacement ...

Invitation to presentation of BioArctic’s third quarter report for July – September 2022 on October 20 at 9.30 a.m. CET

October 14, 2022 - Other press release

Stockholm, Sweden, October 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2022 on Thursday, ...

Latest data on lecanemab presented at Alzheimer’s Association International Conference (AAIC)

August 5, 2022 - Other press release

Stockholm, August 5, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril ...

Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)

July 26, 2022 - Other press release

Stockholm, July 26, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) ...

Invitation to presentation of BioArctic’s second quarter report for April – June 2022 on July 12 at 9.30 a.m. CET

July 5, 2022 - Other press release

Stockholm, Sweden, July 5, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s second quarter report for April – June 2022 on Tuesday, July ...

BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease

May 6, 2022 - Other press release

Stockholm, May 6, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted a new ...

Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years

April 27, 2022 - Other press release

Stockholm, April 27, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational ...

Invitation to presentation of BioArctic’s First Quarter Report for January – March 2022 on April 28 at 9.30 a.m. CET

April 20, 2022 - Other press release

Stockholm, Sweden, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s First Quarter Report for January – March 2022 on ...

Latest lecanemab data to be presented at the AD/PD™ congress

March 11, 2022 - Other press release

Stockholm, March 11, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...

BioArctic continues to build its commercial organization

February 18, 2022 - Other press release

Stockholm, February 18, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the ...

Invitation to presentation of BioArctic’s Full Year Report for January – December 2021 on February 3 at 9.30 a.m. CET

January 27, 2022 - Other press release

Stockholm, Sweden, January 27, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for January – December 2021 on Thursday, February ...

DIAN-TU enrolls first subject for the Tau NexGen study with lecanemab as back-ground anti-amyloid treatment

January 19, 2022 - Other press release

Stockholm, January 19, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led ...

BioArctic develops new antibody treatment for ALS

November 15, 2021 - Other press release

Stockholm, November 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company’s development project ND3014. For the first time, ...

New data on lecanemab presented at the CTAD Alzheimer conference

November 15, 2021 - Other press release

Stockholm, November 15, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai held several oral presentations at the 14[th] Clinical Trials on Alzheimer’s ...

DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer’s disease

November 8, 2021 - Other press release

Stockholm, November 8, 2021 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led ...

New data published on ABBV-0805 in Neurobiology of Disease

November 8, 2021 - Other press release

Stockholm, November 8, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has published an article in Neurobiology of Disease describing new preclinical data for the ...

New data on lecanemab to be presented at the 14[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference

November 4, 2021 - Other press release

Stockholm, November 4, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai today announced that they will hold several oral presentations revealing new ...

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET

October 11, 2021 - Other press release

Stockholm, Sweden, October 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Interim Report for the period January – September 2021 ...

New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease

September 10, 2021 - Other press release

Stockholm, September 10, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-?-synuclein antibody ABBV-0805 at the International ...

Eisai presented latest data from the lecanemab clinical program at AAIC 2021

July 30, 2021 - Other press release

Stockholm, July 30, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, ...

Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)

July 21, 2021 - Other press release

Stockholm, July 21, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer’s Association International Conference (AAIC) to ...

BioArctic receives patent in Japan for new antibodies targeting Alzheimer’s disease

May 11, 2021 - Other press release

Stockholm, May 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) has allowed the company’s ...

Lecanemab (BAN2401) Phase 2b study in early Alzheimer’s disease published in peer-reviewed journal, Alzheimer’s Research & Therapy

April 20, 2021 - Other press release

Stockholm April 20, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b ...

Invitation to presentation of BioArctic’s Interim Report for the period January – March 2021 on April 21 at 9.30 a.m. CET

April 15, 2021 - Other press release

Stockholm, Sweden, April 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Interim Report for the period January – March 2021 ...

BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021

March 15, 2021 - Other press release

Stockholm, March 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the ...

Latest lecanemab data to be presented at the AD/PD™ congress

March 5, 2021 - Other press release

Stockholm, March 5, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...

Eisai increases the number of participants in Clarity AD study

February 3, 2021 - Other press release

Stockholm, February 3, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately ...

BioArctic receives European patent for new antibodies targeting Alzheimer’s disease

January 27, 2021 - Other press release

Stockholm, January 27, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant ...

Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2020 on February 4 at 9.30 a.m. CET

January 26, 2021 - Other press release

Stockholm, Sweden, January 26, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for the period January – December ...

Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020

November 9, 2020 - Other press release

Stockholm, November 9, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the ...

BioArctic’s partner Eisai to present latest data on BAN2401 at CTAD conference

October 28, 2020 - Other press release

Stockholm, October 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will conduct four oral presentations related to ...

BioArctic winner of the Allbright Award 2020

October 15, 2020 - Other press release

Stockholm, October 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its ...

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2020 on October 14 at 9.30 a.m. CET

October 6, 2020 - Other press release

Stockholm, Sweden, October 6, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2020 on Wednesday, ...

Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020

July 30, 2020 - Other press release

Stockholm, July 30, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai presented the latest data from the open-label ...

BioArctic’s partner Eisai to present update on the development of BAN2401 at Alzheimer’s Association International Conference 2020

July 22, 2020 - Other press release

Stockholm, July 22, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will present the study design of the ...

New global Phase 3 program of BAN2401 initiated in preclinical (asymptomatic) Alzheimer’s disease

July 14, 2020 - Other press release

Stockholm, July 14, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its business partner Eisai, in collaboration with Alzheimer’s Clinical Trials Consortium ...

BioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease

June 29, 2020 - Other press release

Stockholm, Sweden, June 29, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they ...

Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401

March 3, 2020 - Other press release

Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the ...

Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2019 on February 6 at 9.30 a.m. CET

January 28, 2020 - Other press release

Stockholm, Sweden, January 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...

BioArctic strengthens its management team with two strategic recruitments

December 10, 2019 - Other press release

Stockholm, Sweden, December 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will be strengthening its management team in 2020 through two strategic recruitments. ...

BioArctic and Eisai to present data on BAN2401 at the Clinical Trials on Alzheimer’s Disease conference

December 2, 2019 - Other press release

Stockholm, Sweden, December 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the 12th ...

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2019 on October 24 at 9.30 a.m. CET

October 16, 2019 - Other press release

Stockholm, Sweden, October 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September ...

BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019

July 18, 2019 - Other press release

Stockholm, Sweden, July 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The ...

BioArctic’s co-founder received AAIC Lifetime Achievement Award

July 15, 2019 - Other press release

Professor Lars Lannfelt received prestigious international award for outstanding research in Alzheimer’s disease

BioArctic and Eisai to present BAN2401 at the Alzheimer’s Association International Conference 2019

July 11, 2019 - Other press release

Stockholm, Sweden, July 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at ...

Invitation to presentation of BioArctic’s Interim Report for the second quarter of 2019 on July 11 at 9.30 a.m. CET

July 2, 2019 - Other press release

Stockholm, Sweden, July 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2019 ...

BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment

May 23, 2019 - Other press release

Stockholm, Sweden, May 23, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. ...

BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease

May 10, 2019 - Other press release

Stockholm, Sweden, May 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer’s Clinical Trials Consortium (ACTC) and BioArctic’s partner ...

BioArctic’s Board of Directors and management increase their shareholdings

May 9, 2019 - Other press release

Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that nine members of the company's Board and management today have called ...

Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET

April 29, 2019 - Other press release

Stockholm, Sweden, April 29, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2019 ...

BioArctic receives grant from Vinnova for a collaborative research project to increase brain uptake of antibodies

April 3, 2019 - Other press release

Stockholm, Sweden, April 3, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 ...

BioArctic’s partner Eisai to give poster presentations on BAN2401 in early Alzheimer’s disease at the AD/PD conference in Lisbon

March 25, 2019 - Other press release

Stockholm, Sweden, March 25, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that its partner Eisai will give poster presentations related to BAN2401 in ...

Invitation to presentation of BioArctic’s Full Year Report 2018 on February 14, 2019

February 7, 2019 - Other press release

Stockholm, Sweden, February 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...

BioArctic employs Gunilla Andersson as Senior Director HR

December 19, 2018 - Other press release

Stockholm, Sweden, December 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Gunilla Andersson assumes the new position as Senior Director HR ...

BioArctic to present at Jefferies 2018 London Healthcare Conference on November 15

November 13, 2018 - Other press release

Stockholm, Sweden, November 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 ...

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018

October 30, 2018 - Other press release

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at ...

BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD

October 18, 2018 - Other press release

Stockholm, Sweden, October 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai will present additional data on the anti-amyloid (Aβ) ...

Proud partner of: